ALIMTA 500 mg powder for concentrate for solution for infusion clinical trials
9 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.
For: Stage IV Non-Small Cell Lung Cancer (NSCLC)Spain · Ireland · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)
This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.
For: Previously Untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)France · Netherlands · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
This study looks at new ways to treat early-stage lung cancer. It compares standard chemotherapy with treatments that combine chemotherapy with new medicines called nivolumab and ipilimumab, to see if they work better at stopping the cancer from returning.
For: Early Stage Non-Small Cell Lung Cancer (NSCLC)France · Italy · Romania - Ongoing, recruitingPhase III and phase IV (Integrated)
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (KEYVIBE-006)
This study is looking at new ways to treat advanced lung cancer that can't be removed by surgery. It compares a new combination of medicines with a standard treatment, both given with chemotherapy and radiotherapy, to see which works best.
For: Non-small cell lung cancerSpain · Italy · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
This study looks at a new combination of treatments for advanced non-small cell lung cancer. It compares a new drug (MK-7684A) plus chemotherapy to an existing drug (pembrolizumab) plus chemotherapy, to see which works better and is safer.
For: Metastatic Non-Small Cell Lung CancerGermany · Spain · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study is testing a new way to treat early-stage lung cancer before surgery. It combines standard chemotherapy with a new drug called Tecentriq, or a dummy drug, to see if it helps patients live longer and stay cancer-free.
For: Early-Stage Resectable Non-small cell lung cancer (NSCLC)Spain · France · Slovenia - Ongoing, recruitingTherapeutic exploratory (Phase II)
OPTIMUNE-LUNG : INTEGRATIVE ANALYSIS OF THE TUMOR MICROENVIRONMENT AND OPTIMIZATION OF THE IMMUNOTHERAPY DURATION IN NON-SMALL CELL LUNG CANCER PATIENTS
This study looks at how long immunotherapy works for people with advanced lung cancer and how it affects their bodies. We're testing different drug combinations to see which works best and for how long, to improve treatment plans.
For: Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.France - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
This study is testing a new cancer 'vaccine' called PDC*lung01 for non-small-cell lung cancer. It checks if it's safe, how well people can tolerate it, and if it helps fight the cancer, sometimes with another drug called anti-PD-1.
For: Non-small-cell lung cancerFrance · Germany · Netherlands - AuthorisedTherapeutic confirmatory (Phase III)
A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC
This study is for people with advanced lung cancer who have responded well to initial immunotherapy. It's looking at whether using less treatment might still be effective, while potentially reducing side effects. Researchers will track how long participants stay well.
For: Patients with advanced · metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.Netherlands